Business Standard

Adar Poonawalla: A rare risk-taking CEO with strong business acumen

Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries

Adar Poonawalla, CEO, Serum Institute
Premium

Poonawalla is perhaps the only Indian vaccine maker who has decided to start making a vaccine (which is still under clinical trials) on “personal risk”

Sohini Das Mumbai
When the Covid-19 pandemic hit, Adar Poonawalla, CEO of Serum Institute, believed that long-term lockdowns wouldn’t help much. Instead, the world needed a vaccine — fast.  In fact, he tweeted on March 26 (when the government announced its first “relief package” of sorts), "Given the scale of disruption a relief package of at least $200 billion should supercharge spending and restore confidence in our economy. We can recover it back through taxes as our growth rate moves beyond 6 per cent. I hope our FM announces this in phases soon.” 

But a vaccine was a sure-fire way to unlock safely

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in